Inhibrx Biosciences, Inc. (NASDAQ:INBX – Get Free Report) Director Kimberly Manhard sold 500 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $110.26, for a total value of $55,130.00. Following the completion of the sale, the director directly owned 8,000 shares in the company, valued at $882,080. This represents a 5.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Kimberly Manhard also recently made the following trade(s):
- On Friday, September 11th, Kimberly Manhard sold 500 shares of Inhibrx Biosciences stock. The shares were sold at an average price of $111.78, for a total transaction of $55,890.00.
- On Tuesday, September 8th, Kimberly Manhard sold 500 shares of Inhibrx Biosciences stock. The stock was sold at an average price of $115.14, for a total transaction of $57,570.00.
Inhibrx Biosciences Trading Down 4.4%
Shares of NASDAQ:INBX opened at $105.61 on Wednesday. The company has a market cap of $1.55 billion, a PE ratio of -11.89 and a beta of 3.66. The company’s 50-day moving average price is $99.40 and its 200 day moving average price is $93.82. Inhibrx Biosciences, Inc. has a fifty-two week low of $26.19 and a fifty-two week high of $155.29. The company has a quick ratio of 5.07, a current ratio of 5.07 and a debt-to-equity ratio of 12.58.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. acquired a new stake in Inhibrx Biosciences during the 2nd quarter valued at $1,923,000. Tidal Investments LLC acquired a new stake in shares of Inhibrx Biosciences in the second quarter worth $964,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Inhibrx Biosciences in the second quarter worth $31,000. NINE MASTS CAPITAL Ltd acquired a new stake in shares of Inhibrx Biosciences in the second quarter worth $284,000. Finally, Harvest Management LLC purchased a new position in shares of Inhibrx Biosciences during the second quarter valued at $246,000. 82.46% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on INBX shares. Wall Street Zen lowered Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. Citigroup reaffirmed a “market perform” rating on shares of Inhibrx Biosciences in a report on Thursday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibrx Biosciences in a research report on Friday. Finally, HC Wainwright assumed coverage on shares of Inhibrx Biosciences in a research report on Monday, August 24th. They issued a “buy” rating and a $245.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $197.50.
Get Our Latest Research Report on INBX
Inhibrx Biosciences Company Profile
Inhibrx Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing biologic medicines for serious diseases with limited treatment options. The company uses a proprietary protein-engineering platform to design novel therapeutic proteins, including multivalent and long-acting biologics intended to selectively affect disease-related biological pathways.
Inhibrx’s development programs have included INBRX-101, also known as efzofitimod, an engineered fibroblast growth factor 1 intended for the treatment of alpha-1 antitrypsin deficiency-associated emphysema and other inflammatory lung conditions.
Read More
- Five stocks we like better than Inhibrx Biosciences
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
